Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2022 Q2- Text added to 2022 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. freshman Avg
|
New words:
Ajanta, Alameda, Andre, Anthony, Ascencio, Atlantic, Ayesha, Bent, Bexarotene, Bionpharma, Bisoprolol, buyer, Clair, consortium, Cruz, death, Deborah, Deficit, Devriendt, enalapril, favorable, fraud, Gillespie, Glaxo, indemnify, indeterminate, Inflation, intervene, Jackson, Jodee, Jodi, John, joint, Keller, Lashanda, Lebeau, Lipofen, longer, Madison, maleate, McGruder, Mid, Norman, Olsen, Pennsylvania, Philadelphia, Postman, reconsideration, Responsive, Ribabutin, Richard, Roque, Salahuddin, Science, SmithKline, St, Stigger, storage, Supreme, transportation, Twentieth, unamortized, USA, venue, wholly, William, Woodard, wrongful
Valuein 2022 Q2 filing- Value in 2022 Q3 filing
Original filings
Filing view